A mGlu2/3 Agonist in the Treatment of PTSD

Trial Profile

A mGlu2/3 Agonist in the Treatment of PTSD

Phase of Trial: Phase I

Latest Information Update: 04 May 2016

At a glance

  • Drugs Pomaglumetad methionil (Primary)
  • Indications Post-traumatic stress disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 29 Apr 2016 Status changed from completed to discontinued because principal investigator no longer at NYU. No data was analyzed
    • 02 Mar 2016 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 26 Jun 2015 Planned End Date changed from 1 Apr 2015 to 1 Dec 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top